TheEdgeResearch
Home / Stocks / GELS

Gelteq Limited Ordinary Shares (GELS)

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$0.56 ▼ -1.75%
Market Cap
$5.1M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
-0.43
52-Wk Range
0.387-2.02
CEO
Nathan Jacob Givoni
Country
AU
Currency
USD

Gelteq Limited Ordinary Shares operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Clayton, VIC, AU. The stock last traded at $0.56, down 1.75% on the session, giving a market capitalisation of $5.1M. On trailing twelve-month figures it carries a trailing P/E of -2.20, a net margin of -2095.3%. Its beta of -0.43 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-2.20
Price / Sales
40.66
Price / Book
0.58
EV / EBITDA
-4.23
Gross margin
100.0%
Operating margin
-1986.0%
Net margin
-2095.3%
Return on equity
Debt / equity
0.36
Current ratio
0.09
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
18
IPO date
2024-10-29
Headquarters
Clayton, VIC, AU
About Gelteq Limited Ordinary Shares

Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.

Comparable companies

Gelteq Limited Ordinary Shares is most often compared with the following Healthcare names:

AYTUBFRGBFRIBGLCCOCPEVGNIMNNIMRNPRPHSBFM
More research on GELS
GELS technical analysis GELS TheEdge Score Compare against peers
Open full interactive analysis & DCF →